ISX-9
Based on 11 publication(s) in Google Scholar
ISX-9 (Isoxazole 9) is a potent inducer of adult neural stem cell differentiation. ISX-9 activates Ca2+ influx through both voltage-gated Ca2+ channels and NMDA receptors and increases neuroD expression. ISX-9 also induces cardiomyogenic differentiation of Notch-activated epicardium-derived cells (NECs).
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.76%
- No. CAS: 832115-62-5
- Fòrmula: C11H10N2O2S
- Peso molecular:234.27
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
Publications Citing Use of MedChemExpress (MCE) ISX-9
More- Adv Sci (Weinh). 2022 May;9(13):e2104682. [Abstract]
- Mater Today Chem. aterials Today Chemistry 12 (2019) 78e84
- Cells. 2026 Mar 18;15(6):539. [Abstract]
- Stem Cell Reports. 2017 Mar 14;8(3):538-547. [Abstract]
- Stem Cells Transl Med. 2024 Mar 15;13(3):255-267. [Abstract]
- Int J Mol Sci. 2023 Feb 14;24(4):3846. [Abstract]
- ACS Chem Neurosci. 2018 Dec 19;9(12):3175-3185. [Abstract]
- bioRxiv. 2025 Aug 07.
- bioRxiv. 2024 November 15.
- Brain Science Advances. 2022 Feb.
- Patent. US20180273906A1.
-
RT-PCR
-
WB
-
WB
-
Histological Imaging/Staining
-
Cell Imaging/Staining
Ver todos los productos específicos de isoformas Calcium Channel
More
Actividad biológica
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 832115-62-5
-
Appearance Solid
-
Peso molecular 234.27
-
Fòrmula C11H10N2O2S
-
Color Off-white to yellow
-
SMILES
O=C(C1=NOC(C2=CC=CS2)=C1)NC3CC3
-
Synonyms
Isoxazole 9
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
Pharmacological Perturbation of Mechanical Contractility Enables Robust Transdifferentiation of Human Fibroblasts into Neurons. [Abstract]2022 May;9(13):e2104682. PMID: 35240008
ISX-9 purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2022 May;9(13):e2104682. [Abstract]
After treatment with Ble and ISX-9 (20–50 µM) for 22 days, neuron-like HFF cells expressed SYT1 and PSD95.
-
-
Cells
Neuronal Differentiation of GBM-Initiating Cells Combined with Elimination of Undifferentiated Cells Preserves Motor Function. [Abstract]2026 Mar 18;15(6):539. PMID: 41892329 -
Stem Cell Reports
2017 Mar 14;8(3):538-547. PMID: 28216149 -
Stem Cells Transl Med
ISX-9 Promotes KGF Secretion From MSCs to Alleviate ALI Through NGFR-ERK-TAU-β-Catenin Signaling Axis. [Abstract]2024 Mar 15;13(3):255-267. PMID: 38159248
ISX-9 purchased from MedChemExpress. Usage Cited in: Stem Cells Transl Med. 2024 Mar 15;13(3):255-267. [Abstract]
RT-qPCR was performed to detect the changes in KGF mRNA levels in BMSCs after the action time of ISX-9 at concentrations of 0,1.25, 2.5, and 5 μM for 12, 24, 48, and72 hours, respectively.
ISX-9 purchased from MedChemExpress. Usage Cited in: Stem Cells Transl Med. 2024 Mar 15;13(3):255-267. [Abstract]
Western blot verified that ISX-9 acted on BMSCs and upregulated NGFR and its downstream proteins.
ISX-9 purchased from MedChemExpress. Usage Cited in: Stem Cells Transl Med. 2024 Mar 15;13(3):255-267. [Abstract]
Western blot was used to detect the effect of the ERK inhibitor U0126 (U0126/10 μM) on changes in downstream NGFR proteins induced by ISX-9 (2.5 μM).
ISX-9 purchased from MedChemExpress. Usage Cited in: Stem Cells Transl Med. 2024 Mar 15;13(3):255-267. [Abstract]
H&E staining was used to assess lung histopathological changes. The image shows that LPS induces lung histopathological changes, while administration of BMSCs and ISX-9 (25 mg/kg, intraperitoneal injection) reduces lung injury.
-
Int J Mol Sci
The Efficiency of Neurospheres Derived from Human Wharton's Jelly Mesenchymal Stem Cells for Spinal Cord Injury Regeneration in Rats. [Abstract]2023 Feb 14;24(4):3846. PMID: 36835256 -
ACS Chem Neurosci
2018 Dec 19;9(12):3175-3185. PMID: 30091580 -
-
-
-
Solvente y solubilidad
DMSO : ≥ 100 mg/mL (426.86 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (10.67 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (10.67 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (275 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Portuguese - PT (394 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Petrik D, et al. Functional and mechanistic exploration of an adult neurogenesis-promoting small molecule. FASEB J. 2012 Aug;26(8):3148-3162. [Content Brief]
[2]. Jay W Schneider, et al. Small-molecule activation of neuronal cell fate. Nat Chem Biol. 2008 Jul;4(7):408-10. [Content Brief]
[3]. Jamie L Russell, et al. Targeting native adult heart progenitors with cardiogenic small molecules. ACS Chem Biol. 2012 Jun 15;7(6):1067-76. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.2686 mL | 21.3429 mL | 42.6858 mL | 106.7145 mL |
| 5 mM | 0.8537 mL | 4.2686 mL | 8.5372 mL | 21.3429 mL | |
| 10 mM | 0.4269 mL | 2.1343 mL | 4.2686 mL | 10.6714 mL | |
| 15 mM | 0.2846 mL | 1.4229 mL | 2.8457 mL | 7.1143 mL | |
| 20 mM | 0.2134 mL | 1.0671 mL | 2.1343 mL | 5.3357 mL | |
| 25 mM | 0.1707 mL | 0.8537 mL | 1.7074 mL | 4.2686 mL | |
| 30 mM | 0.1423 mL | 0.7114 mL | 1.4229 mL | 3.5571 mL | |
| 40 mM | 0.1067 mL | 0.5336 mL | 1.0671 mL | 2.6679 mL | |
| 50 mM | 0.0854 mL | 0.4269 mL | 0.8537 mL | 2.1343 mL | |
| 60 mM | 0.0711 mL | 0.3557 mL | 0.7114 mL | 1.7786 mL | |
| 80 mM | 0.0534 mL | 0.2668 mL | 0.5336 mL | 1.3339 mL | |
| 100 mM | 0.0427 mL | 0.2134 mL | 0.4269 mL | 1.0671 mL |